Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Neurosci ; 40(12): 3711-9, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25350774

ABSTRACT

Mesiotemporal sclerosis (MTS), the most frequent form of drug-resistant temporal lobe epilepsy, often develops after an initial precipitating injury affecting the immature brain. To analyse early processes in epileptogenesis we used the juvenile pilocarpine model to study status epilepticus (SE)-induced changes in expression of key components in the glutamate-glutamine cycle, known to be affected in MTS patients. SE was induced by Li(+) /pilocarpine injection in 21-day-old rats. At 2-19 weeks after SE hippocampal protein expression was analysed by immunohistochemistry and neuron damage by FluoroJade staining. Spontaneous seizures occurred in at least 44% of animals 15-18 weeks after SE. As expected in this model, we did not observe loss of principal hippocampal neurons. Neuron damage was most pronounced in the hilus, where we also detected progressive loss of parvalbumin-positive GABAergic interneurons. Hilar neuron loss (or end-folium sclerosis), a common feature in patients with MTS, was accompanied by a progressively decreased glutamine synthetase (GS)-immunoreactivity from 2 (-15%) to 19 weeks (-33.5%) after SE. Immunoreactivity for excitatory amino-acid transporters, vesicular glutamate transporter 1 and glial fibrillary acidic protein was unaffected. Our data show that SE elicited in 21-day-old rats induces a progressive reduction in hilar GS expression without affecting other key components of the glutamate-glutamine cycle. Reduced expression of glial enzyme GS was first detected 2 weeks after SE, and thus clearly before spontaneous recurrent seizures occurred. These results support the hypothesis that reduced GS expression is an early event in the development of hippocampal sclerosis in MTS patients and emphasize the importance of astrocytes in early epileptogenesis.


Subject(s)
Glutamate-Ammonia Ligase/metabolism , Hippocampus/enzymology , Hippocampus/growth & development , Status Epilepticus/enzymology , Animals , Disease Models, Animal , Glial Fibrillary Acidic Protein/metabolism , Hippocampus/pathology , Immunohistochemistry , Lithium , Male , Neurons/enzymology , Neurons/pathology , Parvalbumins/metabolism , Pilocarpine , Rats, Wistar , Seizures/enzymology , Seizures/pathology , Status Epilepticus/pathology , Vesicular Glutamate Transport Protein 1/metabolism , gamma-Aminobutyric Acid/metabolism
2.
NMR Biomed ; 26(2): 132-40, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22806932

ABSTRACT

Childhood status epilepticus (SE) initiates an epileptogenic process that leads to spontaneous seizures and hippocampal pathology characterized by neuronal loss, gliosis and an imbalance between excitatory and inhibitory neurotransmission. It remains unclear whether these changes are a cause or consequence of chronic epilepsy. In this study, in vivo MRS was used in a post-SE juvenile rat model of temporal lobe epilepsy (TLE) to establish the temporal evolution of hippocampal injury and neurotransmitter imbalance. SE was induced in P21 rats by injection of lithium and pilocarpine. Four and eight weeks after SE, in vivo (1) H and γ-aminobutyric acid (GABA)-edited MRS of the hippocampus was performed in combination with dedicated ex vivo immunohistochemistry for the interpretation and validation of MRS findings. MRS showed a 12% decrease (p<0.0001) in N-acetylaspartate and a 15% increase (p=0.0226) in choline-containing compound concentrations, indicating neuronal death and gliosis, respectively. These results were confirmed by FluoroJade and vimentin staining. Furthermore, severe and progressive decreases in GABA (-41%, p<0.001) and glutamate (Glu) (-17%, p<0.001) were found. The specific severity of GABAergic cell death was confirmed by parvalbumin immunoreactivity (-68%, p<0.001). Unexpectedly, we found changes in glutamine (Gln), the metabolic precursor of both GABA and Glu. Gln increased at 4 weeks (+36%, p<0.001), but returned to control levels at 8 weeks. This decrease was consistent with the simultaneous decrease in glutamine synthase immunoreactivity (-32%, p=0.037). In vivo MRS showed gliosis and (predominantly GABAergic) neuronal loss. In addition, an increase in Gln was detected, accompanied by a decrease in glutamine synthase immunoreactivity. This may reflect glutamine synthase downregulation in order to normalize Gln levels. These changes occurred before spontaneous recurrent seizures were present but, by creating a pre-epileptic state, may play a role in epileptogenesis. MRS can be applied in a clinical setting and may be used as a noninvasive tool to monitor the development of TLE.


Subject(s)
Epilepsy, Temporal Lobe/metabolism , Epilepsy, Temporal Lobe/pathology , Glutamine/metabolism , Hippocampus/metabolism , Hippocampus/pathology , Magnetic Resonance Spectroscopy/methods , gamma-Aminobutyric Acid/metabolism , Animals , Biomarkers/metabolism , Choline/metabolism , Male , Neurons/metabolism , Neurons/pathology , Neurotransmitter Agents/metabolism , Rats , Rats, Wistar
3.
J Neuroimmunol ; 245(1-2): 15-22, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22353418

ABSTRACT

Temporal lobe epilepsy (TLE) is one of the most common focal epilepsy syndromes. In a genome-wide expression study of the human TLE hippocampus we previously showed up-regulation of genes involved in chemokine signalling. Here we investigate in the rat pilocarpine model for TLE, whether changes in chemokine signalling occur during epileptogenesis and are persistent. Therefore we analysed hippocampal protein expression and cellular localisation of CCL2, CCL4, CCR1 and CCR5 after status epilepticus. We found increased CCL4 (but not CCL2) expression in specific populations of hilar astrocytes at 2 and 19 weeks after SE concomitant with a persistent up-regulation of its receptor CCR5. Our results show an early and persistent up-regulation of CCL4/CCR5 signalling during epileptogenesis and suggest that CCL4 signalling, rather than CCL2 signalling, could have a role in the epileptogenic process.


Subject(s)
Chemokine CCL4/metabolism , Epilepsy, Temporal Lobe/immunology , Hippocampus/immunology , Receptors, CCR5/metabolism , Signal Transduction/immunology , Status Epilepticus/immunology , Animals , Animals, Newborn , Astrocytes/immunology , Astrocytes/metabolism , Disease Models, Animal , Epilepsy, Temporal Lobe/metabolism , Hippocampus/metabolism , Male , Rats , Rats, Wistar , Reaction Time/immunology , Status Epilepticus/metabolism , Up-Regulation/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...